HENLIUS Shares Surge Over 8% Following Clinical Trial Approval for Innovative Cancer Treatment

Stock News03-10

HENLIUS (02696) saw its shares rise more than 8%, extending recent gains. At the time of writing, the stock was up 5.08%, trading at HK$69.3, with a turnover of HK$33.731 million. The upward movement follows news that on March 9, the Center for Drug Evaluation (CDE) of China's National Medical Products Administration approved the clinical trial application for HENLIUS's Class 1 new drug, HLX316 for injection. The drug is intended for the treatment of advanced/metastatic solid tumors. Public information indicates that HLX316 is a B7-H3-sialidase fusion protein. As of the announcement date, no B7-H3-targeted sialidase Fc fusion protein has been approved for marketing anywhere in the world. Additionally, the 2026 European Lung Cancer Congress (ELCC) is scheduled to take place from March 25 to 28 in Copenhagen, Denmark. ELCC is a premier academic conference in the field of lung cancer in Europe and globally. At this year's congress, multiple studies on HENLIUS's independently developed innovative anti-PD-1 monoclonal antibody, HANSIZHUANG (serplulimab), have been selected for presentation, covering both small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) treatment areas.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1158284845?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-10 11:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1158284845","market":"sh","top_or_hot":-1,"title":"HENLIUS Shares Surge Over 8% Following Clinical Trial Approval for Innovative Cancer Treatment","media":"Stock News","content":"<p>HENLIUS (02696) saw its shares rise more than 8%, extending recent gains. At the time of writing, the stock was up 5.08%, trading at HK$69.3, with a turnover of HK$33.731 million. The upward movement follows news that on March 9, the Center for Drug Evaluation (CDE) of China's National Medical Products Administration approved the clinical trial application for HENLIUS's Class 1 new drug, HLX316 for injection. The drug is intended for the treatment of advanced/metastatic solid tumors. Public information indicates that HLX316 is a B7-H3-sialidase fusion protein. As of the announcement date, no B7-H3-targeted sialidase Fc fusion protein has been approved for marketing anywhere in the world. Additionally, the 2026 European Lung Cancer Congress (ELCC) is scheduled to take place from March 25 to 28 in Copenhagen, Denmark. ELCC is a premier academic conference in the field of lung cancer in Europe and globally. At this year's congress, multiple studies on HENLIUS's independently developed innovative anti-PD-1 monoclonal antibody, HANSIZHUANG (serplulimab), have been selected for presentation, covering both small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) treatment areas.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HENLIUS Shares Surge Over 8% Following Clinical Trial Approval for Innovative Cancer Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHENLIUS Shares Surge Over 8% Following Clinical Trial Approval for Innovative Cancer Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-03-10 11:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>HENLIUS (02696) saw its shares rise more than 8%, extending recent gains. At the time of writing, the stock was up 5.08%, trading at HK$69.3, with a turnover of HK$33.731 million. The upward movement follows news that on March 9, the Center for Drug Evaluation (CDE) of China's National Medical Products Administration approved the clinical trial application for HENLIUS's Class 1 new drug, HLX316 for injection. The drug is intended for the treatment of advanced/metastatic solid tumors. Public information indicates that HLX316 is a B7-H3-sialidase fusion protein. As of the announcement date, no B7-H3-targeted sialidase Fc fusion protein has been approved for marketing anywhere in the world. Additionally, the 2026 European Lung Cancer Congress (ELCC) is scheduled to take place from March 25 to 28 in Copenhagen, Denmark. ELCC is a premier academic conference in the field of lung cancer in Europe and globally. At this year's congress, multiple studies on HENLIUS's independently developed innovative anti-PD-1 monoclonal antibody, HANSIZHUANG (serplulimab), have been selected for presentation, covering both small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) treatment areas.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HK0000320223.HKD","symbol_name":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) ACC","start_time":0,"source_url":"","article_id":"1158284845","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1158284845","pubTimestamp":1773112466,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"HENLIUS (02696) saw its shares rise more than 8%, extending recent gains. At the time of writing, the stock was up 5.08%, trading at HK$69.3, with a turnover of HK$33.731 million. The upward movement...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HK0000320223.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) ACC","HK0000306701.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) INC","HK0000320264.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) ACC","VXUS":"国际股票ETF-Vanguard","02696":"复宏汉霖","HK0000306685.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) INC","BK4585":"ETF&股票定投概念","BK1161":"生物科技","BK4588":"碎股","HK0000165453.HKD":"华夏精选大中华科技基金 A类港币"},"translate_title":"创新癌症治疗临床试验获得批准后，复宏汉霖股价飙升逾8%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02696":1,"VXUS":1},"content_text":"HENLIUS (02696) saw its shares rise more than 8%, extending recent gains. At the time of writing, the stock was up 5.08%, trading at HK$69.3, with a turnover of HK$33.731 million. The upward movement follows news that on March 9, the Center for Drug Evaluation (CDE) of China's National Medical Products Administration approved the clinical trial application for HENLIUS's Class 1 new drug, HLX316 for injection. The drug is intended for the treatment of advanced/metastatic solid tumors. Public information indicates that HLX316 is a B7-H3-sialidase fusion protein. As of the announcement date, no B7-H3-targeted sialidase Fc fusion protein has been approved for marketing anywhere in the world. Additionally, the 2026 European Lung Cancer Congress (ELCC) is scheduled to take place from March 25 to 28 in Copenhagen, Denmark. ELCC is a premier academic conference in the field of lung cancer in Europe and globally. At this year's congress, multiple studies on HENLIUS's independently developed innovative anti-PD-1 monoclonal antibody, HANSIZHUANG (serplulimab), have been selected for presentation, covering both small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) treatment areas.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1158284845","isCrawlerRequest":true}